Want to see EFTR full AI Analyst Report?
EFTR Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume10.00
Average Volume (3M)79.17K
Market Cap
$2.82K
Enterprise Value$52.50
Total Cash (Recent Filing)$25.38M
Total Debt (Recent Filing)$20.25M
Price to Earnings (P/E)―
Beta-55.39
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,704,409
10 Day Avg. Volume79,165
30 Day Avg. Volume79,165
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-4.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.86
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Innovative Drug DevelopmenteFFECTOR's focus on STRIs represents a novel approach in cancer treatment, potentially offering unique therapeutic options and competitive advantages in the biotechnology sector.
Strategic PartnershipsPartnerships with larger pharmaceutical companies provide financial support and market access, enhancing eFFECTOR's ability to advance drug candidates and potentially achieve commercialization.
Industry PositioneFFECTOR's niche focus on translational control mechanisms positions it uniquely within the biotechnology industry, potentially leading to breakthroughs in cancer treatment.
Bears Say
Financial DistressThe company's financial instability, characterized by declining revenues and negative equity, raises concerns about its ability to sustain operations and invest in R&D long-term.
Negative Cash FlowPersistent negative cash flow indicates operational inefficiencies and dependency on external financing, which could hinder strategic investments and growth initiatives.
Operational InefficienciesHigh operational costs and negative margins suggest inefficiencies that could undermine profitability and competitiveness unless addressed.
eFFECTOR Therapeutics News
EFTR FAQ
What was eFFECTOR Therapeutics’s price range in the past 12 months?
eFFECTOR Therapeutics lowest stock price was $0.02 and its highest was $0.02 in the past 12 months.
What is eFFECTOR Therapeutics’s market cap?
eFFECTOR Therapeutics’s market cap is $2.82K.
When is eFFECTOR Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were eFFECTOR Therapeutics’s earnings last quarter?
Currently, no data Available
Is eFFECTOR Therapeutics overvalued?
According to Wall Street analysts eFFECTOR Therapeutics’s price is currently Overvalued.
Does eFFECTOR Therapeutics pay dividends?
eFFECTOR Therapeutics does not currently pay dividends.
What is eFFECTOR Therapeutics’s EPS estimate?
eFFECTOR Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does eFFECTOR Therapeutics have?
eFFECTOR Therapeutics has 4,704,409 shares outstanding.
What happened to eFFECTOR Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of eFFECTOR Therapeutics?
Currently, no hedge funds are holding shares in EFTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
eFFECTOR Therapeutics
eFFECTOR Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, focused on devising innovative selective translation regulator inhibitors to treat various cancers. The company's primary investigational drug, Tomivosertib, is an orally administered small molecule that targets and inhibits MNK. This compound is currently undergoing a Phase 2b clinical study for patients diagnosed with metastatic non-small cell lung cancer. Furthermore, eFFECTOR is progressing with Zotatifin, another small-molecule therapeutic designed to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 2 clinical trials, exploring its efficacy in treating different solid tumors. A strategic alliance with Pfizer Inc. supports eFFECTOR's work on developing additional eIF4E inhibitors. Founded in 2012, eFFECTOR Therapeutics, Inc. maintains its operational base in Solana Beach, California.